77007
document
5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer : a Southwest Oncology Group Study . A randomized trial was conducted by the Southwest Oncology Group ( SWOG ) in advanced carcinoma of the stomach and pancreas . Patients were assigned to receive monthly 5-fluorouracil 96-hour continuous infusions with either bolus mitomycin-C or oral methyl-CCNU . Mitomycin-C and methyl-CCNU were administered every eight weeks . The 5 FU-mitomycin combination produced a 14 % and 22 % response rate in disseminated stomach and pancreatic carcinoma , respectively . The combination of infusion 5 FU and methyl-CCNU achieved responses in 9 % and 5 % of stomach and pancreatic tumors , respectively . There was no significant difference in survival between limbs for either tumor . Median survival in gastric carcinoma on the 5 FU-mitomycin regimen was 25 weeks vs. 18 weeks on the 5 FU-METHYL-CCNU arm . In pancreatic carcinoma median survival on the mitomycin limb was 19 weeks as compared to 17 weeks on the methyl-CCNU program . Leukopenia was greater for the first course on the mitomycin limb . Regression analysis demonstrated that performance status was the most important pretreatment characteristic for predicting survival in both tumors . Neither 5 FU infusion combination appears to significantly alter the dismal prognosis of advanced upper gastrointestinal neoplasms .
77008
Intervention_Pharmacological
mitomycin-C vs. 5 FU infusion with methyl-CCNU
77009
Intervention_Physical
5-fluorouracil 96-hour continuous infusions
77010
Intervention_Pharmacological
bolus mitomycin-C or oral methyl-CCNU
77011
Intervention_Pharmacological
Mitomycin-C and methyl-CCNU
77012
Intervention_Pharmacological
5 FU-mitomycin combination
77013
Intervention_Pharmacological
combination of infusion 5 FU and methyl-CCNU
77014
Intervention_Pharmacological
5 FU-mitomycin
77015
Intervention_Pharmacological
5 FU-METHYL-CCNU
77016
Intervention_Pharmacological
methyl-CCNU
77017
Intervention_Pharmacological
mitomycin
77018
Intervention_Pharmacological
5 FU infusion
77019
Outcome_Physical
response rate
77020
Outcome_Physical
responses
77021
Outcome_Mortality
difference in survival
77022
Outcome_Mortality
Median survival
77023
Outcome_Mortality
pancreatic carcinoma median survival
77024
Outcome_Physical
Leukopenia
77025
Outcome_Physical
performance status
77026
Outcome_Mortality
survival